{
    "root": "bc5ef851-e144-4d8e-8959-17d142945f4a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KENGREAL",
    "value": "20250521",
    "ingredients": [
        {
            "name": "CANGRELOR",
            "code": "6AQ1Y404U7"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "kengreal indicated adjunct percutaneous coronary intervention ( pci ) reduce risk periprocedural myocardial infarction ( myocardial infarction ) , repeat coronary revascularization , stent thrombosis ( st ) patients treated p2y12 platelet inhibitor given glycoprotein iib/iiia inhibitor [ ( 14.1 ) ] .",
    "contraindications": "kengreal intended via dedicated iv line , reconstitution dilution . ( 2.3 ) administer 30 mcg/kg intravenous ( iv ) bolus prior pci followed immediately 4 mcg/kg/min iv infusion least 2 hours duration procedure , whichever longer . ( 2.1 ) maintain platelet inhibition discontinuation kengreal infusion , administer oral p2y 12 platelet inhibitor . ( 2.2 )",
    "warningsAndPrecautions": "kengreal supplied sterile lyophilized powder single-use 10 ml vials . ndc # 10122-620-01 : 10 ml vial containing 50 mg cangrelor ndc # 10122-620-10 : 10 count 10 ml vials containing 50 mg cangrelor vials kengreal stored usp controlled room temperature , [ 20°c 25°c ( 68°f 77°f ) excursions 15°c 30°c ( 59°f 86°f ) permitted ] . kengreal® registered trademeark chiesi farmaceutici s.p.a. distributed : chiesi usa , inc. cary , nc 27518 us-126-2-spl",
    "adverseReactions": "significant active bleeding ( 4.1 ) hypersensitivity kengreal component product ( 4.2 )",
    "indications_original": "KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical \n                     Studies (\n                     \n                        14.1\n                     \n                     )].",
    "contraindications_original": "KENGREAL is intended for administration via a dedicated IV line, only after reconstitution and dilution. ( 2.3 ) Administer 30 mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer. ( 2.1 ) To maintain platelet inhibition after discontinuation of KENGREAL infusion, administer an oral P2Y 12 platelet inhibitor. ( 2.2 )",
    "warningsAndPrecautions_original": "KENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.\n                  \n                     NDC # 10122-620-01: 10 mL vial containing 50 mg cangrelor\n                     NDC # 10122-620-10: 10 count of 10 mL vials containing 50 mg cangrelor\n                  \n                  Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. \n                  KENGREAL® is a registered trademeark of Chiesi Farmaceutici S.p.A.\n                  Distributed by:\nChiesi USA, Inc. \nCary, NC  27518\n                  US-126-2-SPL",
    "adverseReactions_original": "Significant active bleeding ( 4.1 ) Hypersensitivity to KENGREAL or any component of the product ( 4.2 )"
}